KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) – Leerink Partnrs lowered their Q3 2024 earnings per share (EPS) estimates for KalVista Pharmaceuticals in a research report issued on Tuesday, February 13th. Leerink Partnrs analyst J. Schwartz now expects that the specialty pharmaceutical company will post earnings per share of ($0.69) for the quarter, down from […]
KalVista Pharmaceuticals (NASDAQ:KALV) Reaches New 52-Week High on Analyst Upgrade themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) shares gapped up before the market opened on Friday following insider buying activity. The stock had previously closed at $14.90, but opened at $15.47. KalVista Pharmaceuticals shares last traded at $15.38, with a volume of 33,479 shares changing hands. Specifically, major shareholder Venrock Healthcare Capital Par purchased […]
Insider Selling: KalVista Pharmaceuticals, Inc (NASDAQ:KALV) Insider Sells $224,045 21 in Stock themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Insider Selling: KalVista Pharmaceuticals, Inc (NASDAQ:KALV) Insider Sells 22,679 Shares of Stock theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.